Cardiovascular Risk in Patients with Chronic Kidney Disease with Special Reference to Statin Therapy

Barbagelata L, Masson W, Rossi E, Lee M, Lagoria J, Vilas M, Pizarro R, Rosa Diez G. Cardiovascular risk stratification and appropriate use of statins in patients with chronic kidney disease according to different strategies. High Blood Press Cardiovasc Prev. 2022;29(5):435–43. https://doi.org/10.1007/s40292-022-00531-8. Vega GL, Wang J, Grundy SM. Chronic kidney disease and statin eligibility. J Clin Lipidol. 2021;15(1):173–80. https://doi.org/10.1016/j.jacl.2020.10.004. Zhao L, Li S, Gao Y. Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2021;43(1):718–28. https://doi.org/10.1080/0886022X.2021.1915799. Sandfort V, Lai S, Ahlman MA, et al. Obesity is associated with progression of atherosclerosis during statin treatment. J Am Heart Assoc. 2016;5(7):e003621. https://doi.org/10.1161/JAHA.116.003621. Heine GH, Eller K, Stadler JT, Rogacev KS, Marsche G. Lipid-modifying therapy in chronic kidney disease: pathophysiological and clinical considerations. Pharmacol Ther. 2020;207:107459. https://doi.org/10.1016/j.pharmthera.2019.107459. Esmeijer K, Dekkers OM, de Fijter JW, Dekker FW, Hoogeveen EK. Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Sci Rep. 2019;9(1):16632. https://doi.org/10.1038/s41598-019-53064-x.